The US FDA has given secukinumab the greenlight for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA), following its success in the phase III PREVENT trial, the largest ever for a biologic in nr-axSpa.
The IL-1 receptor antagonist anakinra – a drug for rheumatoid arthritis – demonstrated potential in treating gout, as it reduced gout pain and flares to similar degrees as triamcinolone, results of the ANAGO* study have shown.
The investigational interleukin (IL)-6 inhibitor olokizumab is effective in improving symptoms and physical function of patients with moderate-to-severe rheumatoid arthritis (RA) who are inadequately controlled with methotrexate (MTX), according to the CREDO-1 study presented at the EULAR 2020 Virtual Meeting.
Use of the monoclonal antibody ixekizumab led to improvements in symptoms, work productivity, and overall functioning and health in patients with nonradiographic axial spondyloarthritis (nr-axSpA), subgroup results of the phase III COAST-X trial have shown.
The type I interferon receptor antibody anifrolumab reduced disease activity and flares in patients with moderate-to-severe active systemic lupus erythematosus (SLE), results of the TULIP-1 and TULIP-2 trials have shown.
Treatment with tanezumab, a monoclonal antibody against nerve growth factor, significantly reduces pain intensity and improves daily function in patients with chronic low back pain, according to a trial presented at EULAR 2020.
The anti-interleukin 17A antibody netakimab reduces disease activity and skin manifestations in patients with active psoriatic arthritis (PsA), consequently improving patient-reported outcomes (PROs), analyses of the phase III PATERA trial have shown.
The investigational JAK1* inhibitor filgotinib was noninferior to adalimumab in reducing disease activity in patients with moderate-to-severe rheumatoid arthritis (RA) who had inadequate response to methotrexate (MTX-IR), according to the FINCH 1 study presented at EULAR 2020 Virtual Meeting.
Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.
Treatment with apremilast, an oral phosphodiesterase 4 inhibitor, significantly reduced the number of oral ulcers in patients with Behcet’s syndrome, according to the RELIEF* study presented at EULAR 2020.